Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on hemoglobin, B-type natriuretic peptide, and renal function in anemic heart failure patients: A systematic review and meta-analysis

Article

Author: Kamiya, Takeshi ; Fukuta, Hidekatsu ; Goto, Toshihiko

BackgroundAnemia is a common comorbidity in heart failure (HF) patients, often leading to worsened outcomes. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors represent a novel approach for anemia management, yet their efficacy and safety in HF patients remain unclear. We aimed to conduct a systematic review and meta-analysis of studies on the effects of HIF-PH inhibitors on hemoglobin, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), or estimated glomerular filtration rate (eGFR) in HF patients with chronic kidney disease (CKD).Methods and ResultsThe search of electronic databases identified four studies including 98 patients. Among the included studies, two were conducted prospectively, while two were retrospective in design. No studies were identified that compared HIF-PH inhibitors with erythropoiesis-stimulating agents or placebo. In cases of significant heterogeneity (I² > 50 %), data were pooled using a random-effects model; otherwise, a fixed-effects model was used. In pooled analyses, hemoglobin levels increased at one (weighted mean difference [WMD]: 0.697 [0.473, 0.920] g/dL; P_fix < 0.001; I² = 24 %) and three months (WMD: 0.760 [0.443, 1.076] g/dL; P_fix < 0.001; I² = 31 %) after the use of HIF-PH inhibitors. NT-proBNP levels showed a modest decrease at one month but no significant changes at three months. eGFR remained unchanged, and no severe adverse events were reported.ConclusionThis meta-analysis suggests that HIF-PH inhibitors effectively improve anemia in HF patients with CKD without notable changes in renal or HF-related biomarkers. However, the small number of included studies and the absence of a comparator group underscore the need for cautious interpretation of the findings.

14 Mar 2025·ACS Energy Letters

New Dissolution Chemistry of Nylon Promises Reversible Li-Metal Batteries

Author: Hedhili, Mohamed N. ; Zhao, Zhiming ; Qasem, Hussam ; Alshareef, Husam N. ; Lei, Yongjiu ; Guo, Dong ; Melinte, Georgian ; Shi, Zixiong

Integrating additives into electrolytes serves as an effective strategy for cultivating robust interphases in batteries.Traditionally, the emphasis has been placed on small-mol. additives, whereas macromols. have been largely overlooked due to their insolubility in conventional solvents.In this study, we establish that the macromol. polyamide (nylon, PA) can be effectively solubilized in Li⁺ electrolytes and utilized as a macromol. additive.The dissolution capability of the electrolyte is governed by multiple parameters.Specifically, the dissolution of PA is facilitated by stronger Lewis acidity of the cations, weaker solvating capabilities of the solvents, smaller anions, and higher salt concentrationsAt the mol. level, coordination of cations with carbonyl groups and the formation of H-bonds between anions and amido groups disrupt the crystalline structure of PA, thereby enhancing its solubilityAs a paradigm for practicability, the solubilized PA in carbonate-based electrolytes induces Li₃N-rich interphases, significantly boosting the rechargeability of Li-metal batteries (LMBs).

08 Jan 2025·Japanese Journal of Clinical Oncology

Update on the management of ductal carcinoma in situ of the breast: current approach and future perspectives

Review

Author: Kanbayashi, Chizuko ; Iwata, Hiroji

AbstractThe standard treatment for ductal carcinoma in situ became well established through the results of several valuable clinical trials, and its therapeutic benefits have now come to be taken for granted. Ductal carcinoma in situ has an extremely good prognosis with the current treatment approach, with a 10-year breast cancer-specific survival rate of 97–98%. According to one retrospective cohort study, the breast cancer-specific survival rate of patients with low-grade ductal carcinoma in situ does not differ significantly between patients undergoing and not undergoing surgery. Some patients with ductal carcinoma in situ are not at a risk of progression to invasive cancer, but the predictors of such progression have not yet been clearly identified. Therefore, the same therapeutic strategies have been used to treat ductal carcinoma in situ and under the assumption that they have risks of invasive breast cancer, and a well-balanced risk/benefit ratio in respect of treatment has not yet been achieved. Based on the results of several recent clinical trials aimed at ensuring provision of a well-balanced treatment for patients with ductal carcinoma in situ which carries a good prognosis, de-escalation of postoperative adjuvant therapy has now begun. Currently, not only is the optimization of postoperative adjuvant therapy accelerating, but also clinical trials to de-escalate basic surgical treatments are under way. There is a possibility of achieving individualized treatment for patients with ductal carcinoma in situ of the breast with reduced treatment intervention. In this review, we present an overview of the current treatment approaches and potential future management strategies for ductal carcinoma in situ of the breast.

100 Deals associated with Core Laboratories LP

100 Translational Medicine associated with Core Laboratories LP

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Core Laboratories LP

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 09 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing